Specially Designed Labeled Protein for Car-T Therapy

Home / Specially Designed Labeled Protein for Car-T Therapy

Specially Designed Labeled Protein for Car-T Therapy

For years, the foundations of cancer treatment were surgery, chemotherapy, and radiation therapy. But over the past several years, immunotherapy has emerged as what many in the cancer community now call the “fifth pillar” of cancer treatment.

CAR T-cell therapy is a type of immunotherapy that changes a patient’s own T cells so they are able to recognize and attack cancer. T cells are taken from a patient’s blood. Then the gene for a special receptor that binds to a certain protein on the patient’s cancer cells is added in the laboratory. 

One most import step of CAR-T cell therapy is T cell reengineering, which produce chimeric antigen receptors (CARs) on the surface of the cells. Then these reengineered T cell need to select and collected from others. This is often done by flow cytometry, using protein L, anti-Fab antibodies or target antigens as detection methods. Among these common choices, target antigens are widely considered to be the best option, because it offers high specificity and minimal background staining.

In order to avoid damage to healthy tissues caused by CAR-T cell therapy, the targets must be restricted to tumor cells. However, it is quite difficult to discover an ideal biomarker as an anti-tumor target, which highly expressed on tumor cell surface and rarely expressed on the healthy cell. In a more common situation, the chosen biomarkers express on both tumor cell and healthy ones, with a significant expression level discrimination.

Creative BioMart offers a variety of pre-fluorescent-conjugated and pre-biotinylated recombinant proteins, which are convenient for your cell separation. Featured products are listed below, please contact us for more details or more protein information. We could conjugate specific recombinant proteins according to your custom requirements.

Online Inquiry